News Poxel taking two shots at NASH as pharma waits on FDA's OCA ... Intercept’s obeticholic acid (OCA) is under review in the potentially lucrative fatty liver disease non-alcoholic steatohepatitis (NA
News Trial sets up 2020 filing for Poxel's novel diabetes drug French biotech Poxel has positive phase 3 data for a new type of oral therapy for type 2 diabetes, setting up a first filing in Japan next year.
News Ramaswamy's Roivant signs diabetes drug deal with Poxel Biotech entrepreneur hopes to bounce back from Alzheimer's disappointment
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.